Impact of adjuvant immunochemotherapy using protein-bound polysaccharide-K on overall survival of patients with gastric cancer

Anticancer Research

Volumn 32, Issue 8, 2012, Pages 3427-3433

  Tanaka, Hiroaki ^a   Muguruma, Kazuya ^a   Ohira, Masaichi ^a   Kubo, Naoshi ^a   Yamashita, Yoshito ^a   Maeda, Kiyoshi ^a   Sawada, Tetsuji ^a   Hirakawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adjuvant immunochemotherapy; Gastric cancer; PSK; Survival

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; KRESTIN;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; FEMALE; GASTRECTOMY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTOPERATIVE CARE; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STOMACH CANCER; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; IMMUNOSUPPRESSION; MALE; MIDDLE AGED; PROTEOGLYCANS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84865687915     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Endoh H, Matsunaga K, Yoshikumi C, Kawai Y, Suzuki T and Nomoto K: Production of antiserum against antitumor proteinbound polysaccharide preparation, PSK (Krestin) and its pharmacological application. Int J Immunopharmacol 10: 103-109, 1988.
2. Hirahara N, Fujioka M, Edamatsu T, Fujieda A, Sekine F, Wada T and Tanaka T: Protein-bound polysaccharide-K (PSK) induces apoptosis and inhibits proliferation of promyelomonocytic leukemia HL-60 cells. Anticancer Res 31: 2733-2738, 2011.
3. Kato M, Hirose K, Hakozaki M, Ohno M, Saito Y, Izutani R, Noguchi J, Hori Y, Okumoto S, Kuroda D et al: Induction of gene expression for immunomodulating cytokines in peripheral blood mononuclear cells in response to orally administered PSK, an immunomodulating protein-bound polysaccharide. Cancer Immunol Immunother 40: 152-156, 1995.
4. Zhang H, Morisaki T, Matsunaga H, Sato N, Uchiyama A, Hashizume K, Nagumo F, Tadano J and Katano M: Protein-bound polysaccharide PSK inhibits tumor invasiveness by down-regulation of TGF-beta1 and MMPs. Clin Exp Metastasis 18: 343-352, 2000.
5. Zhang H, Morisaki T, Nakahara C, Matsunaga H, Sato N, Nagumo F, Tadano J and Katano M: PSK-mediated NF-kappaB inhibition augments docetaxel-induced apoptosis in human pancreatic cancer cells NOR-P1. Oncogene 22: 2088-2096, 2003.
6. Ohwada S, Kawate S, Ikeya T, Yokomori T, Kusaba T, Roppongi T, Takahashi T, Nakamura S, Kawashima Y, Nakajima T and Morishita Y: Adjuvant therapy with protein-bound polysaccharide K and tegafur uracil in patients with stage II or III colorectal cancer: randomized, controlled trial. Dis Colon Rectum 46: 1060-1068, 2003.
7. Nakazato H, Koike A, Saji S, Ogawa N and Sakamoto J: Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet 343: 1122-1126, 1994.
8. Oba K, Teramukai S, Kobayashi M, Matsui T, Kodera Y and Sakamoto J: Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer Immunol Immunother 56: 905-911, 2007.
9. Kwon SJ: Evaluation of the 7th UICC TNM Staging System of Gastric Cancer. J Gastric Cancer 11: 78-85, 2011.
10. Jang YJ, Park MS, Park SS, Kim JH, An H, Park SH, Kim SJ, Kim CS and Mok YJ: Surgeon subspecialty as a factor in improving long-term outcomes for gastric cancer: Twenty years of experience in Korea. Arch Surg 145: 1091-1096, 2010.
11. Niimoto M, Hattori T, Tamada R, Sugimachi K, Inokuchi K and Ogawa N: Postoperative adjuvant immunochemotherapy with mitomycin C, futraful and PSK for gastric cancer. An analysis of data on 579 patients followed for five years. Jpn J Surg 18: 681-686, 1988.
12. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A and Arai K: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357: 1810-1820, 2007.
13. Ueda Y, Fujimura T, Kinami S, Hirono Y, Yamaguchi A, Naitoh H, Tani T, Kaji M, Yamagishi H and Miwa K: A randomized phase III trial of postoperative adjuvant therapy with S-1 alone versus S-1 plus PSK for stage II/IIIA gastric cancer: Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC). Jpn J Clin Oncol 36: 519-522, 2006.
14. Nio Y, Tsubono M, Tseng CC, Morimoto H, Kawabata K, Masai Y, Shiraishi T, Imai S, Ohgaki K and Tobe T: Immunomodulation by orally administered protein-bound polysaccharide PSK in patients with gastrointestinal cancer. Biotherapy 4: 117-128, 1992.
15. Sakamoto J, Morita S, Oba K, Matsui T, Kobayashi M, Nakazato H and Ohashi Y: Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer Immunol Immunother 55: 404-411, 2006.
16. Sakai T, Yamashita Y, Maekawa T, Mikami K, Hoshino S and Shirakusa T: Immunochemotherapy with PSK and fluoropyrimidines improves long-term prognosis for curatively resected colorectal cancer. Cancer Biother Radiopharm 23: 461-467, 2008.
17. Asai H, Iijima H, Matsunaga K, Oguchi Y, Katsuno H and Maeda K: Protein-bound polysaccharide K augments IL-2 production from murine mesenteric lymph node CD4+ T cells by modulating T cell receptor signaling. Cancer Immunol Immunother 57: 1647-1655, 2008.
18. Yamaguchi Y, Minami K, Ohshita A, Kawabuchi Y, Noma K and Toge T: Enhancing effect of PS-K on IL-2-induced lymphocyte activation: possible involvement of antagonistic action against TGF-beta. Anticancer Res 24: 639-647, 2004.
19. Iguchi C, Nio Y, Takeda H, Yamasawa K, Hirahara N, Toga T, Itakura M and Tamura K: Plant polysaccharide PSK: cytostatic effects on growth and invasion; modulating effect on the expression of HLA and adhesion molecules on human gastric and colonic tumor cell surface. Anticancer Res 21: 1007-1013, 2001.
20. Hattori TS, Komatsu N, Shichijo S and Itoh K: Protein-bound polysaccharide K induced apoptosis of the human Burkitt lymphoma cell line, Namalwa. Biomed Pharmacother 58: 226-230, 2004.
21. Kono K, Kawaguchi Y, Mizukami Y, Mimura K, Sugai H, Akaike H and Fujii H: Protein-bound polysaccharide K partially prevents apoptosis of circulating T cells induced by anti-cancer drug S-1 in patients with gastric cancer. Oncology 74: 143-149, 2008.
22. Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L and Wolchok J: Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 102: 1388-1397, 2010.
23. Bilusic M and Gulley JL: Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines. Cancer Immunol Immunother 61: 109-117, 2012.
24. Coburn NG: Lymph nodes and gastric cancer. J Surg Oncol 99: 199-206, 2009.
25. Mansfield AS, Heikkila PS, Vaara AT, von Smitten KA, Vakkila JM and Leidenius MH: Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer. BMC Cancer 9: 231, 2009.
26. Camus M, Tosolini M, Mlecnik B, Pages F, Kirilovsky A, Berger A, Costes A, Bindea G, Charoentong P, Bruneval P, Trajanoski Z, Fridman WH and Galon J: Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res 69: 2685-2693, 2009.